Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PCNA | P12004 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772157 | 0.81 | POLB (0.46) | POLBALDH1A1PCNANCEH1TSHR | |
| SCHEMBL3823395 | 0.81 | PCNA (0.43) | ALDH1A1PCNALMNASETDB1 | |
| SCHEMBL3825070 | 0.80 | RIPK1 (0.39) | POLBPCNA | |
| SCHEMBL3825211 | 0.80 | POLQ (0.41) | ALDH1A1PCNALMNAMEN1KMT2A | |
| SCHEMBL2560222 | 0.79 | PTGDR2 (0.44) | ALDH1A1LMNAMEN1KMT2APTGDR2 | |
| SCHEMBL3822915 | 0.79 | PCNA (0.41) | POLBALDH1A1PCNALMNAMEN1 | |
| SCHEMBL30455348 | 0.78 | POLB (0.46) | POLBALDH1A1PCNANCEH1LMNA | |
| SCHEMBL24802582 | 0.78 | POLB (0.63) | POLBALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL10411874 | 0.78 | ALDH1A1 (0.47) | POLBALDH1A1PCNA | |
| SCHEMBL3826988 | 0.77 | PTGDR2 (0.36) | ALDH1A1MEN1KMT2ATSHRSETDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567477-B1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-2090566-A2 | Certain phenylacetic acids and derivatives | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| CN-1729157-A | Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | NOVARTIS AG (CH) | 2006-02-01 | — | — | CN | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | POLB 2164/4885ALDH1A1 99/4885PCNA 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.